NCT00152178View on ClinicalTrials.gov

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)

PHASE3CompletedINTERVENTIONAL
Enrollment

680

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

April 30, 2008

Study Completion Date

August 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

UFT (uracil, tegafur) and tamoxifen

UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.

DRUG

CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen

CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.

Trial Locations (1)

Unknown

Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-1-3, Nakamichi, Higashinari-ku, Osaka

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00152178 - The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) | Biotech Hunter | Biotech Hunter